Immunofoco's In Vivo CAR-T Promises to Transform Cancer Treatment

SHANGHAI – April 20, 2026 – In a presentation that could signal a paradigm shift in cancer treatment, Immunofoco today shared promising preclinical data for IMV102, a novel therapy that engineers cancer-fighting cells directly inside the body. The results, unveiled at the American Association for Cancer Research (AACR) Annual Meeting 2026, suggest the treatment offers potent and durable control of multiple myeloma, a common blood cancer.

This new approach, known as in vivo CAR-T therapy, aims to solve the most persistent challenges plaguing current cell therapies: exorbitant costs, complex manufacturing, and long, anxious waits for patients. If successful in human trials, IMV102 and technologies like it could transform a highly personalized, boutique treatment into a more accessible, 'off-the-shelf' solution for patients worldwide.

The Quest for Accessible Cell Therapy

Chimeric Antigen Receptor T-cell (CAR-T) therapy has been a modern marvel, offering new hope by reprogramming a patient's own immune cells to hunt and destroy cancer. However, this miracle comes with a heavy price. The standard ex vivo process involves drawing a patient's blood, shipping the cells to a specialized lab, genetically modifying them, multiplying them into the millions, and then shipping them back to be infused into the patient.

This bespoke, vein-to-vein journey is a logistical and financial behemoth. The process can take weeks—a dangerously long time for patients with aggressive disease—and costs can soar past $400,000 per patient before hospitalization fees. These barriers significantly limit patient access, creating disparities in care and restricting the therapy's reach to a small number of certified, specialized centers.

Experts agree that for cell therapy to achieve its full potential, a new model is needed. The in vivo approach, pioneered by companies like Immunofoco, represents that new frontier. By delivering the genetic engineering machinery directly to T-cells within the patient, it effectively turns the body into its own bioreactor. This could dramatically slash manufacturing time and costs, potentially making CAR-T therapy as straightforward to administer as a conventional drug.

A Look Inside the iMAGIC Platform

At the heart of Immunofoco's innovation is its proprietary iMAGIC platform, a lentiviral-based system designed for precise in vivo T-cell targeting. The platform is a sophisticated two-part vehicle: it uses a specially mutated glycoprotein (MxV-G-mut) to enter cells, paired with a T-cell targeting module (TCM3) that acts like a GPS to ensure it only delivers its payload to the correct immune cells.

The preclinical data presented at AACR provided a compelling proof-of-concept for this technology. In laboratory studies, IMV102, which targets the BCMA protein prevalent on multiple myeloma cells, demonstrated highly selective delivery. It efficiently transduced T-cells while showing minimal uptake in non-target cells like those in the liver, a critical safety feature for any therapy administered systemically.

Once inside the T-cells, the genetic instructions created potent CAR-T cells that were highly effective at killing multiple myeloma cells. In two different animal models of the disease, a single administration of IMV102 led to significant and durable tumor reduction. Importantly, the therapy appeared safe; the animals maintained a stable body weight, and key markers of immune over-activation, a potential side effect of CAR-T, remained within a manageable range. This suggests a favorable balance between powerful anti-tumor activity and patient safety.

Navigating a Competitive Field

Immunofoco is not alone in the race to develop an in vivo CAR-T therapy. The potential to disrupt the multi-billion dollar cell therapy market has attracted significant investment and scientific talent. The multiple myeloma market alone, where CAR-T therapies already hold a nearly 30% share, is projected to reach over $9 billion by 2035.

One of the most prominent players is Kelonia Therapeutics, which was recently acquired by pharmaceutical giant Eli Lilly. Kelonia's lead candidate, KLN-1010, also an in vivo anti-BCMA CAR-T, is already in Phase 1 clinical trials and has shown impressive early response rates. Other companies, like Orna Therapeutics, are exploring different non-viral delivery methods for their own in vivo programs.

The field is not without its challenges, as evidenced by the early termination of a Phase 1 study for another in vivo candidate, ESO-T01, in 2025. This underscores the immense scientific and clinical hurdles involved in ensuring the safety and efficacy of therapies that permanently alter cells inside the human body. Success will require not only innovative technology but also meticulous clinical development.

A Dual-Engine Powering Future Growth

For Immunofoco, IMV102 is a key component of a broader and more ambitious 'dual-engine' strategy. The company, founded in 2020, is simultaneously advancing both next-generation in vivo therapies and more traditional ex vivo CAR-T treatments for solid tumors. Its lead program, IMC002, is an ex vivo CAR-T for solid tumors that is already in a pivotal Phase III trial in China and has received multiple special regulatory designations from the U.S. FDA.

This diversified approach has attracted significant financial backing, with the company raising approximately $70 million from prominent investors like Vivo Capital and SDIC Venture Capital. This capital is fueling the company's expansion, including a new international headquarters and a state-of-the-art manufacturing facility.

Dr. Minmin Sun, Founder, Chairman, and CEO of Immunofoco, framed the recent data as a validation of this strategy. "We believe in vivo CAR-T has the potential to transform the manufacturing and delivery paradigm of cell therapies, enabling a shift from highly personalized treatments to scalable and accessible solutions," she stated in the press release. "We will continue to advance IMV102 into clinical development and expand the application of the iMAGIC platform across oncology and autoimmune diseases."